Array BioPharma
E474928
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Array BioPharma canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4850372 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Array BioPharma Context triple: [Pfizer, hasSubsidiary, Array BioPharma]
-
A.
Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Array BioPharma Target entity description: Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
A.
Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
-
B.
Ariad Pharmaceuticals
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
-
C.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
D.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above. chosen
Statements (44)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| acquiredBy | Pfizer ⓘ |
| acquisitionDate | 2019 ⓘ |
| collaboratedWith |
AstraZeneca
ⓘ
Celgene ⓘ Novartis ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| developed |
binimetinib
ⓘ
encorafenib ⓘ |
| develops | small-molecule cancer therapies ⓘ |
| employs |
scientists specializing in medicinal chemistry
ⓘ
scientists specializing in oncology drug development ⓘ |
| focusesOn |
oncology
ⓘ
rare diseases ⓘ targeted small-molecule therapies ⓘ |
| foundedIn | 1998 ⓘ |
| hasIndication |
BRAF V600E-mutant colorectal cancer
ⓘ
BRAF-mutant melanoma ⓘ |
| hasPipeline |
early-stage oncology programs
ⓘ
late-stage oncology programs ⓘ |
| hasTherapy |
BRAF inhibitor encorafenib
ⓘ
MEK inhibitor binimetinib ⓘ binimetinib ⓘ encorafenib ⓘ |
| headquartersLocation | Boulder, Colorado ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| knownFor | targeted cancer therapies ⓘ |
| parentCompany | Pfizer ⓘ |
| productType | oral small-molecule drugs ⓘ |
| regulatoryApproval |
FDA approval for encorafenib and binimetinib combination in melanoma
ⓘ
FDA approval for encorafenib in BRAF V600E-mutant metastatic colorectal cancer ⓘ |
| researchFocus |
kinase inhibitors
ⓘ
signal transduction pathways ⓘ |
| specializesIn |
BRAF inhibitors
ⓘ
MEK inhibitors ⓘ |
| state | Colorado ⓘ |
| status | subsidiary of Pfizer ⓘ |
| stockExchange | NASDAQ ⓘ |
| therapeuticArea |
colorectal cancer
ⓘ
melanoma ⓘ solid tumors ⓘ |
| tickerSymbol | ARRY ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Array BioPharma Description of subject: Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.